Japan’s general trading houses are steadily becoming a force to be reckoned with in the pharmaceutical industry — and not…
BUSINESS
Zolbetuximab Accepted for EMA Review in CLDN18.2 Gastric Cancer: Astellas
Astellas Pharma said on July 14 that European regulators have accepted for review its application for zolbetuximab, a first-in-class Claudin 18.2 (CLDN18.2)-targeted monoclonal antibody, for the treatment of certain patients with gastric cancer. The European Medicines Agency (EMA) will review…
To read the full story
Related Article
- Astellas’ Gastric Cancer Drug Vyloy Wins European Approval
September 25, 2024
- Astellas Gets EMA Blessing for Gastric Cancer Drug Zolbetuximab
July 30, 2024
BUSINESS
- Novartis Overhauls Sales Model to Prioritize Solving Regional Treatment Gaps
November 14, 2025
- Keytruda Again Tops Japan Market in July-September: IQVIA
November 14, 2025
- UK Clears Monthly IV Maintenance Dosing for Leqembi: Eisai/Biogen
November 14, 2025
- Kaken Gets Select-Asia Rights to Numab’s Multi-Specific Antibody
November 14, 2025
- Pluvicto, Imaavy, Hernexeos Now Available in Japan
November 13, 2025
A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…